ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,431.60
      -0.04%
      US Tech 100
      19,168.00
      0.52%
      Dow Jones
      38,589.16
      -0.15%
      Brent Oil
      82.275
      0.00%
      Bitcoin
      66,249.47
      0.09%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Dyne Therapeutics Inc (DYN)

      7. Dyne Therapeutics Inc (DYN) News

      DYN

      Dyne Therapeutics (DYN)

      Dyne Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:DYN
      DateTimeSourceHeadlineSymbolCompany
      06/13/20244:40PMGlobeNewswire Inc.Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research CongressNASDAQ:DYNDyne Therapeutics Inc
      06/11/20247:42PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DYNDyne Therapeutics Inc
      06/11/20247:41PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DYNDyne Therapeutics Inc
      06/11/20247:34PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DYNDyne Therapeutics Inc
      06/11/20244:32PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DYNDyne Therapeutics Inc
      06/11/20244:25PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DYNDyne Therapeutics Inc
      06/11/20244:22PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DYNDyne Therapeutics Inc
      05/30/20247:30AMGlobeNewswire Inc.Dyne Therapeutics to Present at Jefferies Global Healthcare ConferenceNASDAQ:DYNDyne Therapeutics Inc
      05/28/20247:30AMGlobeNewswire Inc.Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesNASDAQ:DYNDyne Therapeutics Inc
      05/24/20245:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DYNDyne Therapeutics Inc
      05/24/20245:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DYNDyne Therapeutics Inc
      05/24/20245:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:DYNDyne Therapeutics Inc
      05/22/20249:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DYNDyne Therapeutics Inc
      05/22/20244:30PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:DYNDyne Therapeutics Inc
      05/22/20247:59AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:DYNDyne Therapeutics Inc
      05/21/20248:39PMGlobeNewswire Inc.Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common StockNASDAQ:DYNDyne Therapeutics Inc
      05/20/20246:00PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DYNDyne Therapeutics Inc
      05/20/20244:24PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:DYNDyne Therapeutics Inc
      05/20/20244:01PMGlobeNewswire Inc.Dyne Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:DYNDyne Therapeutics Inc
      05/20/20247:37AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:DYNDyne Therapeutics Inc
      05/20/20246:30AMGlobeNewswire Inc.Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional EndpointsNASDAQ:DYNDyne Therapeutics Inc
      05/19/20248:00AMGlobeNewswire Inc.Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ETNASDAQ:DYNDyne Therapeutics Inc
      05/17/20249:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DYNDyne Therapeutics Inc
      05/17/20249:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DYNDyne Therapeutics Inc
      05/17/20249:03PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DYNDyne Therapeutics Inc
      05/16/20244:26PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DYNDyne Therapeutics Inc
      05/16/20244:23PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DYNDyne Therapeutics Inc
      05/16/20244:18PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DYNDyne Therapeutics Inc
      05/02/20244:10PMGlobeNewswire Inc.Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:DYNDyne Therapeutics Inc
      03/27/20244:05PMGlobeNewswire Inc.Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive OfficerNASDAQ:DYNDyne Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:DYN